The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 12, 2019

Filed:

Sep. 14, 2016
Applicants:

Institut Pasteur, Paris, FR;

Centre National DE LA Recherche Scientifique, Paris, FR;

Universite Pierre ET Marie Curie (Paris 6), Paris, FR;

Inventors:

Christophe Prehaud, Guyancourt, FR;

Monique Lafon, Paris, FR;

Nicolas Wolff, Paris, FR;

Zakir Khan, Lucknow, IN;

Elouan Terrien, Pluherlin, FR;

Sandrine Vitry, Courbevoie, FR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/50 (2006.01); C12N 7/00 (2006.01); C12Q 1/6883 (2018.01); C07K 14/435 (2006.01); C07K 14/005 (2006.01); C12Q 1/70 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6883 (2013.01); C07K 14/005 (2013.01); C07K 14/435 (2013.01); C12N 7/00 (2013.01); C12Q 1/70 (2013.01); G01N 33/5023 (2013.01); G01N 33/5038 (2013.01); G01N 33/5058 (2013.01); C07K 2319/02 (2013.01); C07K 2319/05 (2013.01); C07K 2319/70 (2013.01); C12N 2799/027 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); G01N 2333/705 (2013.01);
Abstract

The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, the polypeptides presenting a high affinity for the PDZ domain of the human MAST2 protein. The invention also relates to polynucleotides, vectors, lentiviral particles, cells as well as compositions containing the same. The invention is also directed to the use of the polypeptides, polynucleotides, vectors, lentiviral particles, cells and compositions in the treatment and/or prevention of a disease, disorder or condition, which alters the Central Nervous System (CNS) and/or the Peripheral Nervous System (PNS). The invention also concerns molecular signatures of cellular genes to determine the neurosurvival and/or neuroprotection activity of a molecule.


Find Patent Forward Citations

Loading…